ODTX — Odyssey Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1882782 ·
Last close
$21.47
Market Cap
$1.03B
52W High
$29.05
52W Low
$15.10
ADV30
320,928
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -46,737,000 | -52,788,000 | 483,850,000 | 82,031,000 | 62,629,000 |
| Mar 2026 | 0 | — | -39,671,000 | -38,262,000 | 229,070,000 | 35,719,000 | 752,764,000 |
| Jun 2025 | 959,000 | — | -42,487,000 | -41,235,000 | — | — | — |
| Mar 2025 | 1,918,000 | — | -44,808,000 | -38,435,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-113,944,000
Investing CF
$116,069,000
Financing CF
$7,503,000
CapEx
$-1,340,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.21
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-606,401,000
Inventory
—
Receivables
—
ST Investments
$140,030,000
EBIT TTM
$-112,363,000
Pretax Income TTM
$-112,379,000
Interest Exp TTM
$16,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$99,000
EBITDA
$-150,270,000
Free Cash Flow
$-85,049,128
Enterprise Value
$894,481,664
Total Cash
$310,575,008
Total Debt
$24,825,000
Shares Out
48,058,527
Trailing EPS
$-3.34
Book Value
$8.79
ROE
-85.5%
ROA
-41.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,976,000 | -161,156,000 | -148,647,000 | 269,788,000 | 758,066,000 | -488,278,000 | -129,468,000 |
| Dec 2024 | 4,472,000 | -135,223,000 | -129,321,000 | 197,435,000 | 579,962,000 | -382,527,000 | -117,471,000 |
| Dec 2023 | 1,037,000 | -133,439,000 | -125,938,000 | 286,521,000 | 549,229,000 | -262,708,000 | -112,728,000 |
| Dec 2022 | 0 | -122,776,000 | -124,665,000 | 317,150,000 | 461,770,000 | -144,620,000 | -99,842,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.36
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GLUE | Monte Rosa Therapeutics, Inc. | $999.02M | $11.71 | — |
| MGTX | MeiraGTx Holdings plc | $1.07B | $11.11 | — |
| SLBT | SL Science Holding Ltd | $1.08B | $1.93 | — |
| VOR | Vor Biopharma Inc. | $1.08B | $18.31 | — |
| CGEM | Cullinan Therapeutics, Inc. | $918.80M | $14.95 | — |
News headlines (Yahoo Finance, 1h cache)
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
2026-09-16 12:00 · Yahoo
Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply
2026-09-14 02:44 · Yahoo
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
2026-08-26 12:00 · Yahoo
Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention
2026-08-11 00:19 · Yahoo
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-04 11:00 · Yahoo
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-06-17 20:15 · Yahoo
A Boston biotech tried to go public last year but pulled back. Now it’s valued at nearly $1B
2026-05-15 16:55 · Yahoo
Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip
2026-05-11 12:31 · Yahoo
Evotec and Odyssey collaborate on AI-enabled R&D
2026-08-07 10:10 · Yahoo
Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
2026-05-08 00:44 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.